World's Best Scientists 2026 revealed!

D-Index & Metrics

Molecular Biology

D-Index
56
Citations
45358
World Ranking
2172
National Ranking
1079

Heidi Greulich publication distribution in Molecular Biology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Molecular Biology in 2026. The highlighted bar marks where Heidi Greulich sits on this spectrum.

47–56 publications: 7 scientists 57–66 publications: 17 scientists 67–76 publications: 65 scientists 77–86 publications: 90 scientists 87–96 publications: 125 scientists 97–106 publications: 131 scientists 107–116 publications: 162 scientists 117–126 publications: 177 scientists 127–136 publications: 158 scientists 137–146 publications: 158 scientists 147–156 publications: 146 scientists 157–166 publications: 159 scientists 167–176 publications: 131 scientists 177–186 publications: 110 scientists 187–196 publications: 112 scientists 197–206 publications: 100 scientists 207–216 publications: 89 scientists 217–226 publications: 98 scientists 227–236 publications: 74 scientists 237–246 publications: 72 scientists 247–256 publications: 63 scientists 257–266 publications: 53 scientists 267–276 publications: 54 scientists 277–286 publications: 49 scientists 287–296 publications: 52 scientists 297–306 publications: 43 scientists 307–316 publications: 46 scientists 317–326 publications: 41 scientists 327–336 publications: 42 scientists 337–346 publications: 31 scientists 347–356 publications: 28 scientists 357–366 publications: 29 scientists 367–376 publications: 26 scientists 377–386 publications: 24 scientists 387–396 publications: 24 scientists 397–406 publications: 14 scientists 407–416 publications: 13 scientists 417–426 publications: 20 scientists 427–436 publications: 12 scientists 437–446 publications: 20 scientists 447–456 publications: 11 scientists 457–466 publications: 10 scientists 467–476 publications: 14 scientists 477–486 publications: 14 scientists 487–496 publications: 10 scientists 497–506 publications: 13 scientists 507–516 publications: 13 scientists 517–526 publications: 2 scientists 527–536 publications: 4 scientists 537–546 publications: 6 scientists 547–556 publications: 8 scientists 557–563 publications: 6 scientists 564+ publications: 100 scientists
47 publications 564+

This scientist: 111 publications — 17th percentile

17% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 564 publications or more.

Heidi Greulich D-index placement in Molecular Biology in 2026

The chart shows the D-index (discipline H-index) distribution of Molecular Biology scientists ranked by Research.com in 2026. The highlighted bar marks where Heidi Greulich sits on this spectrum.

40–41 D-Index: 36 scientists 42–43 D-Index: 101 scientists 44–45 D-Index: 115 scientists 46–47 D-Index: 121 scientists 48–49 D-Index: 118 scientists 50–51 D-Index: 130 scientists 52–53 D-Index: 106 scientists 54–55 D-Index: 116 scientists 56–57 D-Index: 113 scientists 58–59 D-Index: 129 scientists 60–61 D-Index: 120 scientists 62–63 D-Index: 105 scientists 64–65 D-Index: 131 scientists 66–67 D-Index: 95 scientists 68–69 D-Index: 97 scientists 70–71 D-Index: 106 scientists 72–73 D-Index: 83 scientists 74–75 D-Index: 89 scientists 76–77 D-Index: 77 scientists 78–79 D-Index: 70 scientists 80–81 D-Index: 73 scientists 82–83 D-Index: 60 scientists 84–85 D-Index: 48 scientists 86–87 D-Index: 45 scientists 88–89 D-Index: 50 scientists 90–91 D-Index: 31 scientists 92–93 D-Index: 51 scientists 94–95 D-Index: 43 scientists 96–97 D-Index: 38 scientists 98–99 D-Index: 39 scientists 100–101 D-Index: 41 scientists 102–103 D-Index: 29 scientists 104–105 D-Index: 33 scientists 106–107 D-Index: 35 scientists 108–109 D-Index: 20 scientists 110–111 D-Index: 38 scientists 112–113 D-Index: 19 scientists 114–115 D-Index: 28 scientists 116–117 D-Index: 13 scientists 118–119 D-Index: 23 scientists 120–121 D-Index: 16 scientists 122–123 D-Index: 15 scientists 124–125 D-Index: 11 scientists 126–127 D-Index: 21 scientists 128–129 D-Index: 7 scientists 130–131 D-Index: 13 scientists 132–133 D-Index: 14 scientists 134–135 D-Index: 17 scientists 136–137 D-Index: 9 scientists 138–139 D-Index: 8 scientists 140–141 D-Index: 16 scientists 142–143 D-Index: 7 scientists 144 D-Index: 7 scientists 145+ D-Index: 100 scientists
40 D-Index 145+

This scientist: 56 D-Index — 29th percentile

29% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 145 D-Index or more.

Overview

Heidi Greulich is affiliated with the Broad Institute in the United States and has contributed extensively to research in the fields of biochemistry, genetics, molecular biology, and medicine. Their scholarly work encompasses a range of topics chiefly related to molecular biology and oncology, with significant publication output in these domains.

The scientist's research spans several subfields including molecular biology, oncology, pulmonary and respiratory medicine, pharmacology, and cancer research. Specific thematic areas of investigation include lung cancer treatments and mutations, phosphodiesterase function and regulation, signaling pathways in disease, cholinesterase and neurodegenerative diseases, RNA and protein synthesis mechanisms, cancer genomics and diagnostics, and receptor mechanisms and signaling.

Heidi Greulich has published in various scientific venues, with frequent contributions to:

  • Cancer Research
  • Journal of Biological Chemistry
  • Molecular Cancer Therapeutics
  • Cell Chemical Biology
  • Nature Cancer

Notable recent papers authored or co-authored by Heidi Greulich include:

  • "Discovering the anticancer potential of non-oncology drugs by systematic viability profiling," 2020, Nature Cancer
  • "Structure of PDE3A-SLFN12 complex reveals requirements for activation of SLFN12 RNase," 2021, Nature Communications
  • "Velcrin-induced selective cleavage of tRNALeu(TAA) by SLFN12 causes cancer cell death," 2022, Nature Chemical Biology
  • "Mechanistic insights into cancer cell killing through interaction of phosphodiesterase 3A and schlafen family member 12," 2020, Journal of Biological Chemistry
  • "A Role for RAS in V-CRK Transformation," 2025, PubMed

Their frequent collaborators in research include Matthew Meyerson, Andrew D. Cherniack, Colin W. Garvie, Sooncheol Lee, and Bethany Kaplan.

The collected research and publications cover broad scientific inquiries with an emphasis on cancer biology, molecular mechanisms of drug action, and signaling pathway elucidation, demonstrating a multidisciplinary approach to biomedical research.

Best Publications

  • EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

    J. Guillermo Paez;Pasi A. Jänne;Pasi A. Jänne;Jeffrey C. Lee;Sean Tracy

  • The landscape of somatic copy-number alteration across human cancers

    Rameen Beroukhim;Craig H. Mermel;Craig H. Mermel;Dale Porter;Guo Wei

  • Somatic mutations affect key pathways in lung adenocarcinoma

    Li Ding;Gad Getz;David A. Wheeler;Elaine R. Mardis

  • The T790M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP

    Cai-Hong Yun;Kristen E. Mengwasser;Angela V. Toms;Michele S. Woo

  • Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing

    Marcin Imielinski;Alice H. Berger;Alice H. Berger;Peter S. Hammerman;Peter S. Hammerman;Bryan Hernandez

  • BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models.

    D Li;L Ambrogio;L Ambrogio;T Shimamura;S Kubo

  • Characterizing the cancer genome in lung adenocarcinoma

    Barbara A. Weir;Barbara A. Weir;Michele S. Woo;Gad Getz;Sven Perner;Sven Perner

  • Structures of Lung Cancer-Derived Egfr Mutants and Inhibitor Complexes: Mechanism of Activation and Insights Into Differential Inhibitor Sensitivity

    Cai-Hong Yun;Titus J. Boggon;Yiqun Li;Michele S. Woo

  • High-throughput oncogene mutation profiling in human cancer

    Roman K. Thomas;Alissa C. Baker;Ralph M. DeBiasi;Ralph M. DeBiasi;Wendy Winckler;Wendy Winckler

  • Activating mutations in ALK provide a therapeutic target in neuroblastoma

    Rani E. George;Takaomi Sanda;Megan C. Hanna;Stefan Fröhling

  • Landscape of genomic alterations in cervical carcinomas

    Akinyemi I. Ojesina;Lee Lichtenstein;Samuel S. Freeman;Chandra Sekhar Pedamallu

  • Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations

    Trevor J Pugh;Trevor J Pugh;Shyamal Dilhan Weeraratne;Shyamal Dilhan Weeraratne;Tenley C. Archer;Tenley C. Archer;Daniel A. Pomeranz Krummel

  • Oncogenic Transformation by Inhibitor-Sensitive and -Resistant EGFR Mutants

    Heidi Greulich;Tzu-Hsiu Chen;Tzu-Hsiu Chen;Whei Feng;Whei Feng;Pasi A Jänne;Pasi A Jänne

  • Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy.

    Jordi Barretina;Barry S Taylor;Barry S Taylor;Shantanu Banerji;Shantanu Banerji;Alexis H Ramos;Alexis H Ramos

  • Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome.

    Yoon Jae Cho;Aviad Tsherniak;Pablo Tamayo;Sandro Santagata

  • Integrative genomic approaches identify IKBKE as a breast cancer oncogene.

    Jesse S. Boehm;Jean J. Zhao;Jun Yao;So Young Kim

  • Discovering the anti-cancer potential of non-oncology drugs by systematic viability profiling.

    Steven M. Corsello;Steven M. Corsello;Rohith T. Nagari;Ryan D. Spangler;Jordan Rossen

  • Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer

    Peter S. Hammerman;Martin L. Sos;Alex H. Ramos;Chunxiao Xu

  • Inhibitor-Sensitive FGFR1 Amplification in Human Non-Small Cell Lung Cancer

    Amit Dutt;Alex H. Ramos;Alex H. Ramos;Peter Seth Hammerman;Craig Harold Mermel;Craig Harold Mermel

  • Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing

    Roman K. Thomas;Elizabeth Nickerson;Jan F. Simons;Pasi A. Jänne

Frequent Co-Authors

Matthew Meyerson
Matthew Meyerson Harvard University
William R. Sellers
William R. Sellers Harvard University
Levi A. Garraway
Levi A. Garraway Roche (United States)
Kwok-Kin Wong
Kwok-Kin Wong New York University
Gad Getz
Gad Getz Broad Institute
Rameen Beroukhim
Rameen Beroukhim Harvard University
Roman K. Thomas
Roman K. Thomas University of Cologne
Eric S. Lander
Eric S. Lander Broad Institute
Pasi A. Jänne
Pasi A. Jänne Harvard University
Stacey Gabriel
Stacey Gabriel Broad Institute

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

If you’re interested in building on your molecular biology education, several online healthcare degree options are available in the U.S. For those already holding a nursing license, the fastest rn to bsn program online pathways enable many professionals to earn a BSN in as little as 6 months. These accelerated programs are designed for working nurses who want to advance their careers quickly.

For those starting with an associate’s in nursing, asn to fnp programs offer direct bridges to becoming a Family Nurse Practitioner. This provides a streamlined path to advanced degrees and expanded clinical roles. Alternatively, if you have a non-nursing background but want to enter the field, you can explore direct entry msn programs for non nurses online, which are tailored for those seeking a quick transition into nursing at a master’s level.

Choosing the right university is crucial for your career. To compare popular online nursing schools, visit the guide on which school is better snhu vs wgu to review program strengths, flexibility, and outcomes. Exploring these educational pathways can open doors to a variety of advanced roles in molecular biology and healthcare.

Best Scientists Citing Heidi Greulich

Trending Scientists

Recently Published Articles